Paul Hastings LLP advised Xencor, Inc. on the offering. Xencor, Inc. (Nasdaq: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and...
You must be a Standard 1 Year member to access this content.
Paul Hastings advised Viking Therapeutics on the offering. Viking Therapeutics, Inc. (Nasdaq: VKTX) executed its underwritten offering of $632.5 million of shares of its common stock....
You must be a Standard 1 Year member to access this content.
Paul Hastings LLP advised Jasper Therapeutics, Inc., while DLA Piper advised the underwriters. Jasper Therapeutics, Inc. (Nasdaq: JSPR), a clinical-stage biotechnology company focused on developing novel...
You must be a Standard 1 Year member to access this content.
Paul Hastings LLP advised Zededa, Inc. in connection with the round. Zededa, the leader in edge management and orchestration, announced the closing of $72 million in...
You must be a Standard 1 Year member to access this content.
Paul Hastings advised Kyverna Therapeutics in connection with the company’s upsized initial public offering. Kyverna Therapeutics, Inc., a patient-centered clinical-stage biopharmaceutical company focused on developing cell...
You must be a Standard 1 Year member to access this content.
Paul Hastings represented Seelos Therapeutics, Inc. in the offering, and Sichenzia Ross Ference Carmel represented Titan Partners Group. Seelos Theraputics Inc. (NASDAQ: SEEL) announced a $5.55 million public...
You must be a Standard 1 Year member to access this content.
Paul Hastings LLP advised Jasper Therapeutics on the deal. Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a biotechnology company focused on developing novel antibody therapies targeting c-Kit...
You must be a Standard 1 Year member to access this content.
Paul Hastings LLP advised Scilex Holding Company on the deal. Scilex Holding Company announced its agreement to merge with Vickers Vantage Corp. I (VCKA), a special purpose...
You must be a Standard 1 Year member to access this content.
